467 related articles for article (PubMed ID: 26891420)
1. A randomized, placebo-controlled, phase 1/2 study of tivantinib (ARQ 197) in combination with irinotecan and cetuximab in patients with metastatic colorectal cancer with wild-type KRAS who have received first-line systemic therapy.
Eng C; Bessudo A; Hart LL; Severtsev A; Gladkov O; Müller L; Kopp MV; Vladimirov V; Langdon R; Kotiv B; Barni S; Hsu C; Bolotin E; von Roemeling R; Schwartz B; Bendell JC
Int J Cancer; 2016 Jul; 139(1):177-86. PubMed ID: 26891420
[TBL] [Abstract][Full Text] [Related]
2. Biweekly cetuximab plus irinotecan as second-line chemotherapy for patients with irinotecan-refractory and KRAS wild-type metastatic colorectal cancer according to epidermal growth factor receptor expression status.
Kang MJ; Hong YS; Kim KP; Kim SY; Baek JY; Ryu MH; Lee JL; Chang HM; Kim MJ; Chang HJ; Kang YK; Kim TW
Invest New Drugs; 2012 Aug; 30(4):1607-13. PubMed ID: 21706149
[TBL] [Abstract][Full Text] [Related]
3. Phase II Study of Tivantinib and Cetuximab in Patients With KRAS Wild-type Metastatic Colorectal Cancer With Acquired Resistance to EGFR Inhibitors and Emergence of MET Overexpression: Lesson Learned for Future Trials With EGFR/MET Dual Inhibition.
Rimassa L; Bozzarelli S; Pietrantonio F; Cordio S; Lonardi S; Toppo L; Zaniboni A; Bordonaro R; Di Bartolomeo M; Tomasello G; Dadduzio V; Tronconi MC; Piombo C; Giordano L; Gloghini A; Di Tommaso L; Santoro A
Clin Colorectal Cancer; 2019 Jun; 18(2):125-132.e2. PubMed ID: 30846365
[TBL] [Abstract][Full Text] [Related]
4. Phase II trial of biweekly cetuximab and irinotecan as third-line therapy for pretreated KRAS exon 2 wild-type colorectal cancer.
Osumi H; Shinozaki E; Mashima T; Wakatsuki T; Suenaga M; Ichimura T; Ogura M; Ota Y; Nakayama I; Takahari D; Chin K; Miki Y; Yamaguchi K
Cancer Sci; 2018 Aug; 109(8):2567-2575. PubMed ID: 29908105
[TBL] [Abstract][Full Text] [Related]
5. Multicenter phase II study of combination therapy with cetuximab and S-1 in patients with KRAS exon 2 wild-type unresectable colorectal cancer previously treated with irinotecan, oxaliplatin, and fluoropyrimidines (KSCC 0901 study).
Takahashi T; Emi Y; Oki E; Kobayashi K; Tsuji A; Shimokawa M; Tanaka T; Akagi Y; Ogata Y; Baba H; Yoshida K; Natsugoe S; Maehara Y;
Cancer Chemother Pharmacol; 2016 Sep; 78(3):585-93. PubMed ID: 27468920
[TBL] [Abstract][Full Text] [Related]
6. Phase II study of combination chemotherapy with biweekly cetuximab and irinotecan for wild-type KRAS metastatic colorectal cancer refractory to irinotecan, oxaliplatin, and fluoropyrimidines.
Shitara K; Yuki S; Yoshida M; Takahari D; Utsunomiya S; Yokota T; Sato Y; Inaba Y; Tajika M; Kawai H; Yamaura H; Kato M; Yamazaki K; Komatsu Y; Muro K
Invest New Drugs; 2012 Apr; 30(2):787-93. PubMed ID: 21174225
[TBL] [Abstract][Full Text] [Related]
7. Subgroup analysis in RAISE: a randomized, double-blind phase III study of irinotecan, folinic acid, and 5-fluorouracil (FOLFIRI) plus ramucirumab or placebo in patients with metastatic colorectal carcinoma progression.
Obermannová R; Van Cutsem E; Yoshino T; Bodoky G; Prausová J; Garcia-Carbonero R; Ciuleanu T; Garcia Alfonso P; Portnoy D; Cohn A; Yamazaki K; Clingan P; Lonardi S; Kim TW; Yang L; Nasroulah F; Tabernero J
Ann Oncol; 2016 Nov; 27(11):2082-2090. PubMed ID: 27573561
[TBL] [Abstract][Full Text] [Related]
8. PTEN expression and KRAS mutations on primary tumors and metastases in the prediction of benefit from cetuximab plus irinotecan for patients with metastatic colorectal cancer.
Loupakis F; Pollina L; Stasi I; Ruzzo A; Scartozzi M; Santini D; Masi G; Graziano F; Cremolini C; Rulli E; Canestrari E; Funel N; Schiavon G; Petrini I; Magnani M; Tonini G; Campani D; Floriani I; Cascinu S; Falcone A
J Clin Oncol; 2009 Jun; 27(16):2622-9. PubMed ID: 19398573
[TBL] [Abstract][Full Text] [Related]
9. Second-line cetuximab/irinotecan versus oxaliplatin/fluoropyrimidines for metastatic colorectal cancer with wild-type KRAS.
Hong YS; Kim HJ; Park SJ; Kim KP; Lee JL; Park JH; Kim JH; Lim SB; Yu CS; Kim JC; Baek JY; Kim SY; Kim TW
Cancer Sci; 2013 Apr; 104(4):473-80. PubMed ID: 23298313
[TBL] [Abstract][Full Text] [Related]
10. Phase II trial of cetuximab plus irinotecan for oxaliplatin- and irinotecan-based chemotherapy-refractory patients with advanced and/or metastatic colorectal cancer: evaluation of efficacy and safety based on KRAS mutation status (T-CORE0801).
Soeda H; Shimodaira H; Gamoh M; Ando H; Isobe H; Suto T; Takahashi S; Kakudo Y; Amagai K; Mori T; Watanabe M; Yamaguchi T; Kato S; Ishioka C
Oncology; 2014; 87(1):7-20. PubMed ID: 24968756
[TBL] [Abstract][Full Text] [Related]
11. CMAB009 plus irinotecan versus irinotecan-only as second-line treatment after fluoropyrimidine and oxaliplatin failure in KRAS wild-type metastatic colorectal cancer patients: promising findings from a prospective, open-label, randomized, phase III trial.
Shi Y; Li J; Xu J; Sun Y; Wang L; Cheng Y; Liu W; Sun G; Chen Y; Bai L; Zhang Y; He X; Luo Y; Wang Z; Liu Y; Yao Q; Li Y; Qin S; Hu X; Bi F; Zheng R; Ouyang X
Cancer Commun (Lond); 2019 May; 39(1):28. PubMed ID: 31126331
[TBL] [Abstract][Full Text] [Related]
12. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial.
Bennouna J; Hiret S; Bertaut A; Bouché O; Deplanque G; Borel C; François E; Conroy T; Ghiringhelli F; des Guetz G; Seitz JF; Artru P; Hebbar M; Stanbury T; Denis MG; Adenis A; Borg C
JAMA Oncol; 2019 Jan; 5(1):83-90. PubMed ID: 30422156
[TBL] [Abstract][Full Text] [Related]
13. Comparison of Panitumumab Plus Irinotecan and Cetuximab Plus Irinotecan for KRAS Wild-type Metastatic Colorectal Cancer.
Yamaguchi T; Iwasa S; Nagashima K; Ikezawa N; Hamaguchi T; Shoji H; Honma Y; Takashima A; Okita N; Kato K; Yamada Y; Shimada Y
Anticancer Res; 2016 Jul; 36(7):3531-6. PubMed ID: 27354619
[TBL] [Abstract][Full Text] [Related]
14. Abituzumab combined with cetuximab plus irinotecan versus cetuximab plus irinotecan alone for patients with KRAS wild-type metastatic colorectal cancer: the randomised phase I/II POSEIDON trial.
Élez E; Kocáková I; Höhler T; Martens UM; Bokemeyer C; Van Cutsem E; Melichar B; Smakal M; Csőszi T; Topuzov E; Orlova R; Tjulandin S; Rivera F; Straub J; Bruns R; Quaratino S; Tabernero J
Ann Oncol; 2015 Jan; 26(1):132-140. PubMed ID: 25319061
[TBL] [Abstract][Full Text] [Related]
15. FOLFIRI and Cetuximab Every Second Week for First-Line Treatment of KRAS Wild-Type Metastatic Colorectal Cancer According to Phosphatase and Tensin Homolog Expression: A Phase II Study.
Personeni N; Rimassa L; Verusio C; Barni S; Rubino L; Bozzarelli S; Villa E; Carnaghi C; Tronconi MC; Gerardi C; Galli F; Floriani I; Destro A; Raschioni C; Labianca R; Santoro A
Clin Colorectal Cancer; 2015 Sep; 14(3):162-9. PubMed ID: 25861836
[TBL] [Abstract][Full Text] [Related]
16. Randomised phase II study of panitumumab plus irinotecan versus cetuximab plus irinotecan in patients with KRAS wild-type metastatic colorectal cancer refractory to fluoropyrimidine, irinotecan and oxaliplatin (WJOG 6510G).
Sakai D; Taniguchi H; Sugimoto N; Tamura T; Nishina T; Hara H; Esaki T; Denda T; Sakamoto T; Okuda H; Satoh T; Tsushima T; Makiyama A; Tsuda T; Hosokawa A; Kuramochi H; Tokunaga S; Moriwaki T; Yasui H; Ishida H; Tsuji A; Otsu S; Shimokawa H; Baba E; Sato M; Matsumoto S; Ozaki Y; Shinozaki K; Tamagawa H; Goto M; Kadowaki S; Fujii H; Koh Y; Yamazaki K; Hironaka S; Kishimoto J; Boku N; Hyodo I; Muro K
Eur J Cancer; 2020 Aug; 135():11-21. PubMed ID: 32526634
[TBL] [Abstract][Full Text] [Related]
17. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.
Primrose J; Falk S; Finch-Jones M; Valle J; O'Reilly D; Siriwardena A; Hornbuckle J; Peterson M; Rees M; Iveson T; Hickish T; Butler R; Stanton L; Dixon E; Little L; Bowers M; Pugh S; Garden OJ; Cunningham D; Maughan T; Bridgewater J
Lancet Oncol; 2014 May; 15(6):601-11. PubMed ID: 24717919
[TBL] [Abstract][Full Text] [Related]
18. Efficacy, Tolerability, and Biomarker Analyses of Once-Every-2-Weeks Cetuximab Plus First-Line FOLFOX or FOLFIRI in Patients With KRAS or All RAS Wild-Type Metastatic Colorectal Cancer: The Phase 2 APEC Study.
Cheng AL; Cornelio G; Shen L; Price T; Yang TS; Chung IJ; Dai GH; Lin JK; Sharma A; Yeh KH; Ma B; Zaatar A; Guan Z; Masood N; Srimuninnimit V; Yau T; Gibbs P; Wang X; Doval DC; Oh ST; Shim BY; Gorospe C; Wang HM; Sirachainan E; Hill A; Suh KW; Beier F; Chatterjee S; Lim R
Clin Colorectal Cancer; 2017 Jun; 16(2):e73-e88. PubMed ID: 27780749
[TBL] [Abstract][Full Text] [Related]
19. Cetuximab plus irinotecan after irinotecan failure in elderly metastatic colorectal cancer patients: clinical outcome according to KRAS and BRAF mutational status.
Fornaro L; Baldi GG; Masi G; Allegrini G; Loupakis F; Vasile E; Cupini S; Stasi I; Salvatore L; Cremolini C; Vincenzi B; Santini D; Tonini G; Graziano F; Ruzzo A; Canestrari E; Magnani M; Falcone A
Crit Rev Oncol Hematol; 2011 Jun; 78(3):243-51. PubMed ID: 20619672
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and toxicity of adding cetuximab to chemotherapy in the treatment of metastatic colorectal cancer: a meta-analysis from 12 randomized controlled trials.
Lv ZC; Ning JY; Chen HB
Tumour Biol; 2014 Dec; 35(12):11741-50. PubMed ID: 25417200
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]